Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 1, 2014, Pages 21-31

  Picchio, M ^a,b   Kirienko, M ^c   Mapelli, P ^a   Dell'Oca, I ^a   Villa, E ^a   Gallivanone, F ^b   Gianolli, L ^a   Messa, C ^b,c,d   Castiglioni, I ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

Author keywords

Head and neck cancer; Metabolic tumour volume; Partial volume effect correction; Predictive value; SUV; Total lesion glycolysis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; GLYCOLYSIS; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; LOCAL RECURRENCE FREE SURVIVAL; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY TUMOR; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ENDPOINT DETERMINATION; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, IMAGE-GUIDED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890804395     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2528-2     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Licitra L, Locati LD, Bossi P. Head and neck cancer. Ann Oncol 2004;15 Suppl 4:iv267-73. doi: 10.1093/annonc/mdh937.
3. Peponi E, Glanzmann C, Kunz G, Renner C, Tomuschat K, Studer G. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in nasopharyngeal cancer. Strahlenther Onkol 2010;186:135-42. doi: 10.1007/s00066-010-2048-y.
4. Heron DE, Andrade RS, Flickinger J, Johnson J, Agarwala SS, Wu A, et al. Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys 2004;60:1419-24. doi: 10.1016/j.ijrobp.2004.05.037.
5. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005;46:1342-8.
6. Du XL, Jiang T, Sheng XG, Li QS, Wang C, Yu H. PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer. Eur J Radiol 2012;81:3551-6. doi: 10.1016/j.ejrad.2012.03.016.
7. Nguyen NP, Chi A, Betz M, Almeida F, Vos P, Davis R, et al. Feasibility of intensity-modulated and image-guided radiotherapy for functional organ preservation in locally advanced laryngeal cancer. PLoS One 2012;7:e42729. doi: 10.1371/journal.pone.0042729.
8. Duet M, Hugonnet F, Faraggi M. Role of positron emission tomography (PET) in head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2010;127:40-5. doi: 10.1016/j.anorl.2010.02.010.
9. Mak D, Corry J, Lau E, Rischin D, Hicks RJ. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging 2011;55:487-99.
10. Murakami R, Uozumi H, Hirai T, Nishimura R, Shiraishi S, Ota K, et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007;68:377-82. doi: 10.1016/j.ijrobp.2006.12.032.
11. Zanation AM, Sutton DK, Couch ME, Weissler MC, Shockley WW, Shores CG. Use, accuracy, and implications for patient management of [18F]-2- fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope 2005;115:1186-90. doi: 10.1097/01.MLG.0000163763.89647.9F.
12. Abgral R, Querellou S, Potard G, Le Roux PY, Le Duc-Pennec A, Marianovski R, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-9. doi: 10.2967/jnumed.108.055806.
13. Ong SC, Schöder H, Lee NY, Patel SG, Carlson D, Fury M, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49:532-40. doi: 10.2967/jnumed.107.044792.
14. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002;86:512-6. doi: 10.1038/sj.bjc.6600114.
15. Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck 2013;35:15-22. doi: 10.1002/hed.22904.
16. Schinagl DA, Span PN, Oyen WJ, Kaanders JH. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging 2011;38:1449-58. doi: 10.1007/s00259-011-1789-x.
17. Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 2010;49:201-8. doi: 10.3109/02841860903440270.
18. Soto DE, Kessler ML, Piert M, Eisbruch A. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol 2008;89:13-8. doi: 10.1016/j.radonc.2008.05.021.
19. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006;80:151-6. doi: 10.1016/j.radonc.2006.07.033.
20. Hatt M, Le Pogam A, Visvikis D, Pradier O, Cheze Le Rest C. Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer. J Nucl Med 2012;53:12-20.
21. van Heijl M, Omloo JM, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW, Boellaard R. Influence of ROI definition, partial volume correction and SUV normalization on SUV-survival correlation in oesophageal cancer. Nucl Med Commun 2010;31:652-8.
22. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45. doi: 10.2967/jnumed.106.035774.
23. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-4. doi: 10.1245/s10434-010-0985-4.
24. Bettinardi V, Mancosu P, Danna M, Giovacchini G, Landoni C, Picchio M, et al. Two-dimensional vs three-dimensional imaging in whole body oncologic PET/CT: a Discovery-STE phantom and patient study. Q J Nucl Med Mol Imaging 2007;51:214-23.
25. Lee JA. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol 2010;96:302-7. doi: 10.1016/j.radonc.2010.07.003.
26. Gallivanone F, Grosso E, Canevari C, Gianolli L, Messa C, Gilardi MC, et al. PVE correction in PET-CT whole-body oncological studies from PVE-affected images. IEEE Trans Nucl Sci 2011;58:736-47. doi: 10.1109/TNS.2011.2108316.
27. Kubicek GJ, Champ C, Fogh S, Wang F, Reddy E, Intenzo C, et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol 2010;2:19. doi: 10.1186/1758-3284-2-19.
28. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:1335-41. doi: 10.1016/j.ijrobp.2008.10.060.
29. Vernon MR, Maheshwari M, Schultz CJ, Michel MA, Wong SJ, Campbell BH, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 2008;70:678-84. doi: 10.1016/j.ijrobp.2007.10.044.
30. Romesser PB, Qureshi MM, Subramaniam RM, Sakai O, Jalisi S, Truong MT. A prognostic volumetric threshold of gross tumor volume in head and neck cancer patients treated with radiotherapy. Am J Clin Oncol 2012. doi: 10.1097/COC.0b013e31826e04d6.
31. Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, et al. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;82:1823-30. doi: 10.1016/j.ijrobp.2010.10.053.
32. Romesser PB, Qureshi MM, Shah BA, Chatburn LT, Jalisi S, Devaiah AK, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med 2012;26:527-34. doi: 10.1007/s12149-012-0604-5.
33. Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Grégoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol 2003;69:247-50.
34. Vanderstraeten B, Duthoy W, De Gersem W, De Neve W, Thierens H. [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 2006;79:249-58.